文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-PSMA PET/CT显示输尿管尿路上皮癌摄取一例

68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer.
PubMed 文献 · Clin Nucl Med · 2020-01-01

一例73岁前列腺癌生化复发患者行68Ga-PSMA PET/CT,发现左输尿管远端一处PSMA摄取灶,组织学证实为低级别非浸润性乳头状尿路上皮癌,免疫组化显示肿瘤尿路上皮细胞及乳头结构血管均有PSMA表达。提示68Ga-PSMA摄取并非前列腺癌特异,其他肿瘤新生血管等组织也可摄取。

要点

  • 68Ga-PSMA PET/CT在非前列腺癌组织中也可见摄取,包括其他肿瘤的新生血管。
  • 本例左输尿管远端PSMA摄取灶经组织学证实为低级别非浸润性乳头状尿路上皮癌。
  • 免疫组化显示PSMA表达见于肿瘤尿路上皮细胞及乳头结构血管。

核心结论

  • 68Ga-PSMA PET/CT的PSMA摄取并非前列腺癌特异,尿路上皮癌等非前列腺癌组织也可出现摄取,判读时需警惕假阳性。

研究设计与样本

  • 本文为单例病例报告,描述一名73岁前列腺癌生化复发患者行68Ga-PSMA PET/CT检查及后续组织学与免疫组化结果。

主要发现

  • 68Ga-PSMA PET/CT显示左输尿管远端一处PSMA摄取灶。
  • 组织学证实该病灶为低级别非浸润性乳头状尿路上皮癌。
  • 免疫组化显示PSMA表达见于肿瘤尿路上皮细胞及乳头结构血管。

临床怎么用

  • 前列腺癌生化复发患者行68Ga-PSMA PET/CT时,对前列腺癌之外部位的PSMA摄取灶应结合临床及病理鉴别,避免误判为转移。

局限性

  • 本文为单例病例报告,结论的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ga-PSMA PET/CT has become a well-established imaging modality to detect prostate cancer (PCa) metastases in biochemical recurrence. Despite its claimed specificity for PCa, Ga-PSMA uptake in tissues unrelated to PCa, particularly in the neovascular tissue of other cancers, has been reported in numerous studies. A 73-year-old man underwent Ga-PSMA PET/CT for biochemical recurrence of PCa 7 years after radical prostatectomy. The Ga-PSMA PET/CT showed 1 lesion with PSMA uptake in the distal left ureter. Histology revealed a low-grade noninvasive papillary urothelial carcinoma. By immunohistochemistry, PSMA expression was observed in the neoplastic urothelial cells and in the vessels of the papillary structures.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zacho HD, Pedersen SH, Petersen A, et al. 68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer. Clin Nucl Med. 2020. PMID: 31306199. doi:10.1097/RLU.0000000000002720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。